Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers

N. Aoyama, Yusuke Tanigawara, T. Kita, T. Sakai, K. Shirakawa, D. Shirasaka, F. Kodama, K. Okumura, M. Kasuga

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Omeprazole is widely used for the treatment of Helicobacter pylori infection. It is metabolized by cytochrome P450 2C19 enzyme (CYP2C19) in the liver. Because this enzyme exhibits a genetic polymorphism, patients with low metabolic activity (poor metabolizers) may be exposed to higher concentrations of this drug than are patients who are extensive metabolizers. Eighty-six patients with cultured H. pylori-positive gastritis or peptic ulcers who completed the treatment and assessment of anti-H. pylori therapy were analyzed for CYP2C19 genotyping using a ploymerase chain reaction-restriction fragment length polymorphism method [the wild-type or two mutant genes (m1 in exon 5 and m2 in exon 4), or both]. Patients were classified into three groups according to the H. pylori eradication regimen: group I (n = 21; omeprazole 40 mg/day and amoxicillin 2000 mg/day for 1 week); group II (n = 21; group I regimen plus sucralfate 4000 mg/day, for 1 week); group III (n = 44; group I regimen plus clarithromycin 800 mg/day, for 1 week). The combination of two mutant alleles (m1/m1, m1/m2, m2/m2-poor metabolizers) was observed in 13 of 86 patients (15), and all poor metabolizer patients achieved H. pylori eradication regardless of their treatment regimens. In addition, the eradication rates of the poor metabolizers were significantly higher than those of other genotypes who carry homozygous or heterozygous normal allele (extensive metabolizers) in group I or groups I and II combined. CYP2C19 genotyping can provide a new strategy to choose an optimal regimen, and this genotyping is especially useful for Japanese, as the frequency of poor metabolizers is five times greater than that found among Caucasians.

Original languageEnglish
Pages (from-to)80-83
Number of pages4
JournalJournal of Gastroenterology
Volume34
Issue numberSUPPL. 11
Publication statusPublished - 1999 Dec
Externally publishedYes

Fingerprint

Omeprazole
Amoxicillin
Helicobacter pylori
Cytochrome P-450 Enzyme System
Exons
Therapeutics
Alleles
Sucralfate
Clarithromycin
Helicobacter Infections
Gastritis
Genetic Polymorphisms
Peptic Ulcer
Restriction Fragment Length Polymorphisms
Genotype
Liver
Enzymes
Pharmaceutical Preparations
Genes

Keywords

  • CYP2C19
  • Dual treatment
  • H. pylori eradication
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. / Aoyama, N.; Tanigawara, Yusuke; Kita, T.; Sakai, T.; Shirakawa, K.; Shirasaka, D.; Kodama, F.; Okumura, K.; Kasuga, M.

In: Journal of Gastroenterology, Vol. 34, No. SUPPL. 11, 12.1999, p. 80-83.

Research output: Contribution to journalArticle

Aoyama, N, Tanigawara, Y, Kita, T, Sakai, T, Shirakawa, K, Shirasaka, D, Kodama, F, Okumura, K & Kasuga, M 1999, 'Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers', Journal of Gastroenterology, vol. 34, no. SUPPL. 11, pp. 80-83.
Aoyama, N. ; Tanigawara, Yusuke ; Kita, T. ; Sakai, T. ; Shirakawa, K. ; Shirasaka, D. ; Kodama, F. ; Okumura, K. ; Kasuga, M. / Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. In: Journal of Gastroenterology. 1999 ; Vol. 34, No. SUPPL. 11. pp. 80-83.
@article{310fb16be5cc4cc0b7dbac12e9b8f5e4,
title = "Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers",
abstract = "Omeprazole is widely used for the treatment of Helicobacter pylori infection. It is metabolized by cytochrome P450 2C19 enzyme (CYP2C19) in the liver. Because this enzyme exhibits a genetic polymorphism, patients with low metabolic activity (poor metabolizers) may be exposed to higher concentrations of this drug than are patients who are extensive metabolizers. Eighty-six patients with cultured H. pylori-positive gastritis or peptic ulcers who completed the treatment and assessment of anti-H. pylori therapy were analyzed for CYP2C19 genotyping using a ploymerase chain reaction-restriction fragment length polymorphism method [the wild-type or two mutant genes (m1 in exon 5 and m2 in exon 4), or both]. Patients were classified into three groups according to the H. pylori eradication regimen: group I (n = 21; omeprazole 40 mg/day and amoxicillin 2000 mg/day for 1 week); group II (n = 21; group I regimen plus sucralfate 4000 mg/day, for 1 week); group III (n = 44; group I regimen plus clarithromycin 800 mg/day, for 1 week). The combination of two mutant alleles (m1/m1, m1/m2, m2/m2-poor metabolizers) was observed in 13 of 86 patients (15), and all poor metabolizer patients achieved H. pylori eradication regardless of their treatment regimens. In addition, the eradication rates of the poor metabolizers were significantly higher than those of other genotypes who carry homozygous or heterozygous normal allele (extensive metabolizers) in group I or groups I and II combined. CYP2C19 genotyping can provide a new strategy to choose an optimal regimen, and this genotyping is especially useful for Japanese, as the frequency of poor metabolizers is five times greater than that found among Caucasians.",
keywords = "CYP2C19, Dual treatment, H. pylori eradication, Proton pump inhibitor",
author = "N. Aoyama and Yusuke Tanigawara and T. Kita and T. Sakai and K. Shirakawa and D. Shirasaka and F. Kodama and K. Okumura and M. Kasuga",
year = "1999",
month = "12",
language = "English",
volume = "34",
pages = "80--83",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "SUPPL. 11",

}

TY - JOUR

T1 - Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers

AU - Aoyama, N.

AU - Tanigawara, Yusuke

AU - Kita, T.

AU - Sakai, T.

AU - Shirakawa, K.

AU - Shirasaka, D.

AU - Kodama, F.

AU - Okumura, K.

AU - Kasuga, M.

PY - 1999/12

Y1 - 1999/12

N2 - Omeprazole is widely used for the treatment of Helicobacter pylori infection. It is metabolized by cytochrome P450 2C19 enzyme (CYP2C19) in the liver. Because this enzyme exhibits a genetic polymorphism, patients with low metabolic activity (poor metabolizers) may be exposed to higher concentrations of this drug than are patients who are extensive metabolizers. Eighty-six patients with cultured H. pylori-positive gastritis or peptic ulcers who completed the treatment and assessment of anti-H. pylori therapy were analyzed for CYP2C19 genotyping using a ploymerase chain reaction-restriction fragment length polymorphism method [the wild-type or two mutant genes (m1 in exon 5 and m2 in exon 4), or both]. Patients were classified into three groups according to the H. pylori eradication regimen: group I (n = 21; omeprazole 40 mg/day and amoxicillin 2000 mg/day for 1 week); group II (n = 21; group I regimen plus sucralfate 4000 mg/day, for 1 week); group III (n = 44; group I regimen plus clarithromycin 800 mg/day, for 1 week). The combination of two mutant alleles (m1/m1, m1/m2, m2/m2-poor metabolizers) was observed in 13 of 86 patients (15), and all poor metabolizer patients achieved H. pylori eradication regardless of their treatment regimens. In addition, the eradication rates of the poor metabolizers were significantly higher than those of other genotypes who carry homozygous or heterozygous normal allele (extensive metabolizers) in group I or groups I and II combined. CYP2C19 genotyping can provide a new strategy to choose an optimal regimen, and this genotyping is especially useful for Japanese, as the frequency of poor metabolizers is five times greater than that found among Caucasians.

AB - Omeprazole is widely used for the treatment of Helicobacter pylori infection. It is metabolized by cytochrome P450 2C19 enzyme (CYP2C19) in the liver. Because this enzyme exhibits a genetic polymorphism, patients with low metabolic activity (poor metabolizers) may be exposed to higher concentrations of this drug than are patients who are extensive metabolizers. Eighty-six patients with cultured H. pylori-positive gastritis or peptic ulcers who completed the treatment and assessment of anti-H. pylori therapy were analyzed for CYP2C19 genotyping using a ploymerase chain reaction-restriction fragment length polymorphism method [the wild-type or two mutant genes (m1 in exon 5 and m2 in exon 4), or both]. Patients were classified into three groups according to the H. pylori eradication regimen: group I (n = 21; omeprazole 40 mg/day and amoxicillin 2000 mg/day for 1 week); group II (n = 21; group I regimen plus sucralfate 4000 mg/day, for 1 week); group III (n = 44; group I regimen plus clarithromycin 800 mg/day, for 1 week). The combination of two mutant alleles (m1/m1, m1/m2, m2/m2-poor metabolizers) was observed in 13 of 86 patients (15), and all poor metabolizer patients achieved H. pylori eradication regardless of their treatment regimens. In addition, the eradication rates of the poor metabolizers were significantly higher than those of other genotypes who carry homozygous or heterozygous normal allele (extensive metabolizers) in group I or groups I and II combined. CYP2C19 genotyping can provide a new strategy to choose an optimal regimen, and this genotyping is especially useful for Japanese, as the frequency of poor metabolizers is five times greater than that found among Caucasians.

KW - CYP2C19

KW - Dual treatment

KW - H. pylori eradication

KW - Proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0033383967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033383967&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 80

EP - 83

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - SUPPL. 11

ER -